Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) Shares Outstanding (Weighted Average): 2015-2025

Historic Shares Outstanding (Weighted Average) for Intellia Therapeutics (NTLA) over the last 10 years, with Sep 2025 value amounting to $107.3 million.

  • Intellia Therapeutics' Shares Outstanding (Weighted Average) rose 5.68% to $107.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $107.3 million, marking a year-over-year increase of 5.68%. This contributed to the annual value of $101.8 million for FY2024, which is 13.73% up from last year.
  • Per Intellia Therapeutics' latest filing, its Shares Outstanding (Weighted Average) stood at $107.3 million for Q3 2025, which was up 3.63% from $103.6 million recorded in Q2 2025.
  • In the past 5 years, Intellia Therapeutics' Shares Outstanding (Weighted Average) registered a high of $107.3 million during Q3 2025, and its lowest value of $67.7 million during Q1 2021.
  • Over the past 3 years, Intellia Therapeutics' median Shares Outstanding (Weighted Average) value was $96.5 million (recorded in 2024), while the average stood at $96.8 million.
  • Data for Intellia Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY surged of 34.09% (in 2021) over the last 5 years.
  • Over the past 5 years, Intellia Therapeutics' Shares Outstanding (Weighted Average) (Quarterly) stood at $74.4 million in 2021, then climbed by 5.73% to $78.7 million in 2022, then increased by 13.82% to $89.6 million in 2023, then climbed by 13.73% to $101.8 million in 2024, then increased by 5.68% to $107.3 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $107.3 million for Q3 2025, versus $103.6 million for Q2 2025 and $103.5 million for Q1 2025.